Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation

General Inclusion Criteria: * Age ≥ 18 years; * Subjects (or legal guardians) understand the testing requirements and procedures, and provide written informed consent; * Subjects with symptomatic coronary artery disease or confirmed asymptomatic ischemia; * Target lesion should be new lesion with visually estimated reference diameter ≥2.5 mm and ≤4.0 mm in autologous coronary artery; * Subjects willing to accept PCI therapy and to implant Firehawk™ stent only; * Left ventricular ejection fraction (LVEF) ≥ 30%; * Subjects willing to accept the trial plan calls for all subsequent evaluations. Angiographic Inclusion Criteria: * Target lesions must be new and have a visually estimated reference diameter ≥2.5 mm and ≤4.0 mm in autologous coronary artery; * No limitations in target lesion length and number; * The first target lesion must be able to successfully expand and implant Firehawk™ stent. Clinical Exclusion Criteria: * Subjects with ST-segment elevation myocardial infarction: * Subjects having an organ transplant or waiting for an organ transplant * Subjects receiving chemotherapy or going to receive a chemotherapy within 30 days after PCI * Subjects undergoing chronic (over 72 hours) anticoagulant therapy (such as heparin and coumarin) other than acute coronary syndrome * Subjects with abnormal counts of platelet and white blood cell (WBC) (investigator assess clinical significance combine normal reference range of laboratory) * Subjects with confirmed or suspected liver disease, including hepatitis lab results * Subjects with elevated serum creatinine level \>3.0mg/dL or undergoing dialysis therapy * Subjects with active peptic ulcer, active gastrointestinal (GI) bleeding or other bleeding diathesis or coagulopathy, or refused a blood transfusion * Subjects with cerebral vascular accident (CVA) or transient ischemic attack (TIA) in the past 6 months, or with permanent nerve defects * Subjects undergoing any PCI treatment in target vessels within 12 months prior to baseline * Subjects planned to undergo PCI or CABG within 18 months after the baseline PCI * Subjects with a history of any coronary endovascular brachytherapy treatment previously * Subjects associated with drugs allergy (such as sirolimus, or structure-related compounds fluorinated polymers, thienopyridine or aspirin) * Subjects being suffered from other serious illness (such as cancer, congestive heart failure), which may cause drop in life expectancy to less than 18 months * Subjects with a history of drug abuse (such as alcohol, cocaine, heroin, etc.) * Subject planned to undergo any operations that may lead to confuse with the programme * Subjects participating in another study of drug or medical device which did not meet its primary endpoint * Subjects planned to pregnant within 18 months after baseline * Pregnant or breastfeeding women Angiographic Exclusion Criteria: * Target lesions with the following criteria: left main, saphenous vein grafts or arterial grafts, via saphenous vein grafts or arterial graft, and in-stent restenosis; * Subjects with unprotected left main coronary artery disease (diameter stenosis \>50%); * Protected left main coronary artery disease(diameter stenosis \>50% and undergoing CABG)with target lesions located in left anterior descending artery and left circumflex artery; * Additional lesions of clinical significance possibly needing interventional within 18 months after enrollment..